Saturday, Esperion Presented Results From Two CLEAR Outcomes Study Late-Breakers At European Society of Cardiology Congress 2023, Cardiovascular Event Analysis, Bempedoic Acid Shows 20%, 17% Risk Reduction In MACE-4, MACE-3, Respectively
Portfolio Pulse from Benzinga Newsdesk
Esperion presented results from two CLEAR Outcomes Study late-breakers at the European Society of Cardiology Congress 2023. The cardiovascular event analysis showed that Bempedoic Acid resulted in a 20% and 17% risk reduction in MACE-4 and MACE-3 respectively. The analysis was conducted on patients with diabetes.
August 28, 2023 | 8:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion's Bempedoic Acid shows promising results in reducing cardiovascular risk in patients with diabetes. This could potentially boost the company's market position and stock value.
The positive results from the CLEAR Outcomes Study presented by Esperion at the European Society of Cardiology Congress 2023 indicate a potential increase in the demand for Bempedoic Acid. This could lead to increased revenues for the company, thereby potentially boosting its stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100